Home › Endometrial Cancer › Illinois › Bloomington
Endometrial Cancer clinical trials in Bloomington, IL
3 studies for Endometrial Cancer are looking for participants at sites in and around Bloomington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- Illinois CancerCare-Bloomington, Bloomington
- Carle BroMenn Medical Center, Normal · 2 mi away
- Carle Cancer Institute Normal, Normal · 2 mi away
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RecruitingPhase 3
- Carle BroMenn Medical Center, Normal · 2 mi away
- Carle Cancer Institute Normal, Normal · 2 mi away
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RecruitingPhase 2
- Carle BroMenn Medical Center, Normal · 2 mi away
- Carle Cancer Institute Normal, Normal · 2 mi away
Endometrial Cancer trials in other cities
- Houston, TX68 studies
- New York City, NY52 studies
- Boston, MA50 studies
- Arlington, VA39 studies
- Nashville, TN38 studies
- Los Angeles, CA34 studies
- St. Louis, MO29 studies
- Philadelphia, PA28 studies
- San Antonio, TX27 studies
- Chicago, IL25 studies
- Columbus, OH25 studies
- Queens, NY25 studies
Other studies in Bloomington
- Non-Small Cell Lung Cancer11 studies
- Lung Cancer9 studies
- Prostate Cancer7 studies
- Colorectal Cancer7 studies
- Head and Neck Squamous Cell Carcinoma6 studies
- Pancreatic Cancer5 studies
- Melanoma5 studies
- Hypopharyngeal Cancer5 studies
- Laryngeal Cancer5 studies
- Oral Cancer5 studies
- Breast Cancer5 studies
- Kidney Cancer (Renal Cell Carcinoma)4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.